上海莱士: 关于通过境外反垄断审查暨收购南岳生物制药有限公司股权的进展公告

Core Viewpoint - Shanghai Laishi Blood Products Co., Ltd. has made progress in acquiring a majority stake in Nanyue Biopharmaceutical Co., Ltd. and has received necessary approvals from foreign antitrust review agencies [1][2]. Group 1: Acquisition Details - The company signed an equity transfer agreement to acquire a total of 87.9766% of Nanyue Biopharmaceutical from Liu Ling'an and other parties [1]. - Additionally, the company signed an agreement to acquire 12.0234% of Nanyue Biopharmaceutical from Hunan Xingxiang Fund [1]. Group 2: Regulatory Approvals - The company has obtained all necessary approvals from foreign antitrust review agencies as required by local laws prior to the completion of the transaction [1]. Group 3: Transaction Status - The transaction has not yet been officially completed, and relevant work is currently in progress [2]. - The company will closely monitor the progress of the transaction and fulfill its information disclosure obligations in accordance with relevant laws and regulations [2].